A recent study from the University of California, San Francisco (UCSF), highlights how hormonal changes during menopause can accelerate the progression of multiple sclerosis (MS), significantly affecting patients’ mobility, cognition, and dexterity.
Key Findings from the Study
The study, published in Neurology, tracked 184 women for 13 years using data from UCSF’s EPIC and ORIGINS studies. Researchers observed:
- Mobility Declines: Postmenopausal women took longer to complete a 25-foot walk, even after accounting for age and lifestyle factors.
- Cognitive and Dexterity Impairments: Subtle declines in fine motor skills and cognitive function were observed.
- Biomarker Evidence: Higher levels of neurofilament light chain (NfL) in the blood, a marker of nerve cell degeneration, validated these findings.
The Role of Hormones in Multiple Sclerosis
Women represent 75% of multiple sclerosis patients, with hormonal changes playing a pivotal role in the disease’s trajectory.
- Puberty and MS Risk: Hormonal shifts during puberty can trigger autoimmune responses.
- Pregnancy Effects: Relapse rates drop during the third trimester of pregnancy, followed by a postpartum rebound, further underscoring the influence of hormones.
Implications for Hormone Therapy
While only 17% of study participants used estrogen therapy, this wasn’t enough to draw definitive conclusions about its efficacy. However, animal research and small human trials suggest that sex hormones, including testosterone, may have neuroprotective benefits.
What This Means for Multiple Sclerosis Patients
The study highlights menopause as a critical factor in MS progression, separate from aging. It calls for large-scale randomized trials to explore the potential benefits of hormone therapy for MS.
Practical Takeaways for MS Management
- Mobility Monitoring: Patients and doctors should monitor walking speed and dexterity during menopause.
- Biomarker Insights: Tracking neurofilament light chain levels could provide early signs of disease progression.
- Potential Role of Hormones: While promising, hormone therapy needs more research to confirm its benefits and safety.
Be a part of HerHealth Congress 2025 for more insights on women’s health.
More Information: University of California – San Francisco
more recommended stories
-
Heart Failure Risk Cut Post-Attack with PR-364 Drug
Researchers at Cedars-Sinai Medical Center have.
-
PTSD, Anxiety Linked to Lower Ovarian Reserve in Firefighters
A recent study by the University.
-
Art, Nature, and Meditation: Unique Brain Activation Patterns
Recent studies have shown that practices.
-
Only 1 in 4 Share Heart Data From Devices With Doctors
Modern technology enables individuals to monitor.
-
Biometric Data Reveals Mood Insights in Shift Workers
The COVID-19 pandemic highlighted the global.
-
Azvudine Cuts COVID-19 Deaths, Outperforming Paxlovid
COVID-19 has caused a global health.
-
Aspirin Fails to Prevent Colorectal Cancer Recurrence in Trial
Colorectal cancer remains a global health.
-
Huntington’s Prevention: Biomarkers Offer Early Detection
Huntington’s Disease: Detecting the Silent Progression.
-
U.S. Water Quality: Racial Disparities in Exposure
A new analysis by the Silent.
-
Pediatric Epilepsy Incidence and ILAE Classification Insights
This 2025 Epilepsia study provides a comprehensive.
Leave a Comment